Certolizumab pegol
| Klinički podaci | |
|---|---|
| Drugs.com | pegol.html Monografija |
| Način primene | Subkutano |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 14 dana |
| Identifikatori | |
| CAS broj | 428863-50-7  Y |
| ATC kod | L04AB05 (WHO) |
| DrugBank | DB08904 Y |
| ChEMBL | CHEMBL1201831 Y |
| Hemijski podaci | |
| Formula | C2115H3252N556O673S16 |
| Molarna masa | 47.75 kDa |
Certolizumab pegol je recombinantni Fab' fragment antitela provi faktora nekroze tumora-alfa, koji je konjugovan sa oko 40 kDa polietilen glikola (PEG2MAL40K). Polietilen glikol pomaže u usporavanju metabolizma i eliminacije leka. Hemijski, laki lanac se sastoji od 214 aminokiselina, dok teški lanac ima 229 aminokiselina. Molekulska masa Fab' fragmenta antitela je 47,8 kDa. Ovaj lek se koristi u tretmanu reumatoidnog artritisa i Kronove bolesti. FDA je odobrila ovaj lek u aprilu 2008.[1][2][3][4][5]
Reference
- ^ Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R: Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther. 2013 Apr 15;7:339-48. doi: 10.2147/DDDT.S31658. Print 2013. PMID 23620660
- ^ Ferrante M, Vermeire S, Rutgeerts P: Certolizumab pegol in the treatment of Crohn's disease. Expert Opin Biol Ther. 2013 Apr;13(4):595-605. doi: 10.1517/14712598.2013.777039. Epub 2013 Mar 4. PMID 23451881
- ^ https://data.epo.org/publication-server/rest/v1.0/publication-dates/20110803/patents/EP1534753NWB1/document.html[мртва веза]
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126. уреди - ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. уреди
Literatura
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
- Certolizumab pegol
- п
- р
- у
Humanizovana monoklonalna antitela ("-zu-")
Afutuzumab, Alemtuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab§, Milatuzumab, Nimotuzumab, Oportuzumab monatox, Pertuzumab, Sibrotuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab
imunosupresivni: Aselizumab, Apolizumab, Benralizumab†, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, PRO 140†, Reslizumab, Rontalizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412§
non-imunosupresivni: Ibalizumab†
non-imunosupresivni: Ibalizumab†
Tefibazumab†
Alacizumab pegol, Bevacizumab/Ranibizumab, Etaracizumab, Tadocizumab
Bapineuzumab†, Solanezumab, Tanezumab
Urtoksazumab
Felvizumab, Motavizumab, Palivizumab
Lebrikizumab
†U kliničkim ispitivanjima. §Nije bio u prodaji.
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
Certolizumab pegol na srodnim projektima Vikipedije:
Mediji na Ostavi
Podaci na Vikipodacima
